Diabetes Device Engineering | Implanting Cell Replacement Therapies
Practical Cure Project Update: ViaCyte — Juvenile Diabetes Cure Alliance
Pin on Diabetes
CRISPR and ViaCyte dose first subject in Phase I T1D therapy trial
ViaCyte - Posts | Facebook
Viacyte Receives Funding to Continue Developing Beta Cell Therapies - JDRF
Xconomy: ViaCyte Reports on Stem Cell Diabetes Trial, Absorbs BetaLogics
First Human Clinical Trial of Stem Cell-Derived Implants For Type 1 Diabetes
ViaCyte | Regenerative Medicine Therapies for Diabetes
Finally, a possible long-term treatment for type 1 diabetes | UCI Health | Orange County, CA
ViaCyte on Twitter: "Nov. 6: ViaCyte VP, Research and CSO Kevin D'Amour to speak at @ISSCR's “From Stem Cell Biology to New Therapies” https://t.co/f8anGrT6wi #ISSCR #biotech #Toronto #health #T1D #type1diabetes #diabetes #regenerativemedicine #
ViaCyte Announces Second Clinical Trial Site at University of Alberta
ViaCyte (@ViaCyte) / Twitter
First Patient Dosed in Phase 1 Clinical Trial for T1D | The Stem Cellar
Frontiers | Stem Cell-Based Clinical Trials for Diabetes Mellitus | Endocrinology
Diabetes Device Engineering | Implanting Cell Replacement Therapies
Will ViaCyte's Encaptra Cell Delivery System 'Cure' Type 1 Diabetes? | Insulin Nation
Breakthrough Technologies for Cell Replacement Therapies for Diabetes| ViaCyte
JDRF Reports: First-in-Human Gene-Edited Stem Cell Trial? Check.
ViaCyte (@ViaCyte) / Twitter
CIRM-supported Type I Diabetes treatment enters clinical trials in Europe | The Stem Cellar
ViaCyte Acquires Rights to BetaLogics Assets
